Treatment of atrial fibrillation in a district general hospital.

G. Y. Lip, K. N. Tean, F. G. Dunn

Department of Cardiology, Stobhill General Hospital, Glasgow.

OBJECTIVE--To assess current strategies used to investigate and manage acute atrial fibrillation in hospital. DESIGN--Prospective survey of all acute admissions over 6 months. SETTING--District general hospital serving a population of 230,000 in north east Glasgow. SUBJECTS--2686 patients admitted as emergency cases over 6 months. RESULTS--Of the 2686 patients, 170 (age range 38-95, mean (SD) 73.5 (10.6) years; 70 men (41%) and 100 women (59%)) were admitted with atrial fibrillation. The principal underlying medical conditions were ischaemic heart disease in 79 (46.5%), rheumatic heart disease in 26 (15.3%), and thyroid disease in six (3.5%). Cardiac failure was present on admission in 61 (36%), cerebrovascular events in 23 (14%), and myocardial infarction in 17 (10%). Of those with a history of atrial fibrillation (102 (60%) including 10 with paroxysmal atrial fibrillation) treatment on admission included digoxin in 71 (70%), warfarin in 20 (20%), and aspirin in 17 (17%); the aspirin was predominantly given for concomitant vascular disease. The mean (SD) inpatient stay was 16 days (19.7) (range 1-154) largely due to the patients with stroke. Thyroid function tests were performed in only 63% and echocardiography in 33%. Overall, the rate of introduction of anticoagulation (seven patients) and attempted cardioversion (21 patient: 19 pharmacological and two electrical) was surprisingly low. Only 49 patients (34% of those not on warfarin) had contraindications to anticoagulation: these included peptic ulcer or gastrointestinal bleeding in 18 (12%), dementia in eight (6%), chronic renal failure or dialysis in eight (6%), and alcohol excess in four (3%). CONCLUSION--Standard investigations were inadequately used in patients with atrial fibrillation and there was a reluctance to perform cardioversion or to start anticoagulant treatment.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Khoo, C. W., Lip, G. Y. H. (2009). Acute Management of Atrial Fibrillation. Chest 135: 849-859 [Abstract] [Full Text]  
• Camm, A. J., Reiffel, J. A. (2008). Defining endpoints in clinical trials on atrial fibrillation. Eur Heart J Suppl 10: H55-H78 [Abstract] [Full Text]  
• Dewar, R I, Lip, G Y H, on behalf of the Guidelines Development Group for, (2007). Identification, diagnosis and assessment of atrial fibrillation. Heart 93: 25-28 [Full Text]  
• Voller, H. (2005). In defence of current treatment options: where are we now?. Eur Heart J Suppl 7: E4-E9 [Full Text]  
• Kristensen, L, Nielsen, J C, Mortensen, P T, Pedersen, O L, Pedersen, A K, Andersen, H R (2004). Incidence of atrial fibrillation and thromboembolism in a randomised trial of atrial versus dual chamber pacing in 177 patients with sick sinus syndrome. Heart 90: 661-666 [Abstract] [Full Text]  
• Stellbrink, C., Nixdorff, U., Hofmann, T., Lehmacher, W., Daniel, W. G., Hanrath, P., Geller, C., Mugge, A., Sehnert, W., Schmidt-Lucke, C., Schmidt-Lucke, J.-A., on Behalf of the ACE (Anticoagulation in Cardiover, (2004). Safety and Efficacy of Enoxaparin Compared With Unfractionated Heparin and Oral Anticoagulants for Prevention of Thromboembolic Complications in Cardioversion of Nonvalvular Atrial Fibrillation: The Anticoagulation in Cardioversion using Enoxaparin (ACE) Trial. Circulation 109: 997-1003 [Abstract] [Full Text]  
• Funk, M., Richards, S. B., Desjardins, J., Bebon, C., Wilcox, H. (2003). Incidence, Timing, Symptoms, and Risk Factors for Atrial Fibrillation After Cardiac Surgery. Am J Crit Care 12: 424-433 [Abstract] [Full Text]  
• Gronefeld, G.C., Hohnloser, S.H. (2003). Quality of life in atrial fibrillation: an increasingly important issue. Eur Heart J Suppl 5: H25-H33 [Abstract]  
• Gronefeld, G. C., Lilienthal, J., Kuck, K.-H., Hohnloser, S. H., for the Pharmacological Intervention in Atrial Fib, (2003). Impact of rate versus rhythm control on quality of life in patients with persistent atrial fibrillation: Results from a prospective randomized study. Eur Heart J 24: 1430-1436 [Abstract] [Full Text]  
• Freestone, B., Lip, G. Y.H., Scott, P. A., Pancioli, A. M. (2003). Anticoagulation Uptake in Emergency Department Patients With Atrial Fibrillation. Stroke 34: 591-591 [Full Text]  
• Williams, E., Ansari, M., Lip, G.Y.H. (2001). Managing atrial fibrillation in the Accident and Emergency department. QJM 94: 609-614 [Abstract] [Full Text]  
• Frykman, V., Beerman, B., Ryden, L., Rosenqvist, M. (2001). Management of atrial fibrillation: discrepancy between guideline recommendations and actual practice exposes patients to risk for complications. Eur Heart J 22: 1954-1959 [Abstract]  
• Go, A. S., Hylek, E. M., Phillips, K. A., Chang, Y., Henault, L. E., Selby, J. V., Singer, D. E. (2001). Prevalence of Diagnosed Atrial Fibrillation in Adults: National Implications for Rhythm Management and Stroke Prevention: the AnTicoagulation and Risk Factors In Atrial Fibrillation (ATRIA) Study. JAMA 285: 2370-2375 [Abstract] [Full Text]  
• Stewart, S., MacIntyre, K., MacLeod, M.M.C., Bailey, A.E.M., Capewell, S., McMurray, J.J.V. (2001). Trends in hospital activity, morbidity and case fatality related to atrial fibrillation in Scotland, 1986-1996. Eur Heart J 22: 693-701 [Abstract]  
• Bungard, T. J., Ghali, W. A., Teo, K. K., McAlister, F. A., Tsuyuki, R. T. (2000). Why Do Patients With Atrial Fibrillation Not Receive Warfarin?. Arch Intern Med 160: 41-46 [Abstract] [Full Text]  
• Lip, G.Y.H. (1999). Atrial fibrillation and mortality. Eur Heart J 20: 1525-1527  
• Gullov, A. L., Koefoed, B. G., Petersen, P. (1999). Bleeding During Warfarin and Aspirin Therapy in Patients With Atrial Fibrillation: The AFASAK 2 Study. Arch Intern Med 159: 1322-1328 [Abstract] [Full Text]  
• Andersen, H R, Nielsen, J C, Thomsen, P E B, Thuesen, L, Pedersen, A K, Mortensen, P T, Vesterlund, T (1999). Arterial thromboembolism in patients with sick sinus syndrome: prediction from pacing mode, atrial fibrillation, and echocardiographic findings. Heart 81: 412-418 [Abstract] [Full Text]  
• Albers, G. W. (1998). Choice of Antithrombotic Therapy for Stroke Prevention in Atrial Fibrillation: Warfarin, Aspirin, or Both?. Arch Intern Med 158: 1487-1491 [Full Text]  
• Gullov, A. L., Koefoed, B. G., Petersen, P., Pedersen, T. S., Andersen, E. D., Godtfredsen, J., Boysen, G. (1998). Fixed Minidose Warfarin and Aspirin Alone and in Combination vs Adjusted-Dose Warfarin for Stroke Prevention in Atrial Fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. Arch Intern Med 158: 1513-1521 [Abstract] [Full Text]  
• Gage, B. F., Cardinalli, A. B., Owens, D. K. (1998). Cost-Effectiveness of Preference-Based Antithrombotic Therapy for Patients With Nonvalvular Atrial Fibrillation. Stroke 29: 1083-1091 [Abstract] [Full Text]  
• Thomson, R., McElroy, H., Sudlow, M. (1998). Guidelines on anticoagulant treatment in atrial fibrillation in Great Britain: variation in content and implications for treatment. BMJ 316: 509-513 [Abstract] [Full Text]  
• HEE, F L L. S., WONG, P. S C, LIP, G. Y H (1997). Atrial fibrillation begets trouble. Heart 78: 421-421 [Full Text]  
• Whittle, J., Wickenheiser, L., Venditti, L. N. (1997). Is Warfarin Underused in the Treatment of Elderly Persons With Atrial Fibrillation?. Arch Intern Med 157: 441-445 [Abstract]  
• Brodsky, M. A., Chun, J. G., Podrid, P. J., Douban, S., Allen, B. J., Cygan, R. (1996). Regional Attitudes of Generalists, Specialists, and Subspecialists About Management of Atrial Fibrillation. Arch Intern Med 156: 2553-2562 [Abstract]  
• Albers, G. W., Yim, J. M., Belew, K. M., Bittar, N., Hattemer, C. R., Phillips, B. G., Kemp, S., Hall, E. A., Morton, D. J., Vlasses, P. H. (1996). Status of Antithrombotic Therapy for Patients With Atrial Fibrillation in University Hospitals. Arch Intern Med 156: 2311-2316 [Abstract]  
• Man-Son-Hing, M., Laupacis, A., O'Connor, A., Wells, G., Lemelin, J., Wood, W., Dermer, M. (1996). Warfarin for Atrial Fibrillation: The Patient's Perspective. Arch Intern Med 156: 1841-1848 [Abstract]  
• Lip, G. Y.H., Lip, P. L., Zarifis, J., Watson, R. D.S., Bareford, D., Lowe, G. D.O., Beevers, D. G. (1996). Fibrin D-Dimer and ß-Thromboglobulin as Markers of Thrombogenesis and Platelet Activation in Atrial Fibrillation: Effects of Introducing Ultra–Low-Dose Warfarin and Aspirin. Circulation 94: 425-431 [Abstract] [Full Text]  
• Lip, G. Y H (1996). Author's reply. BMJ 312: 641b-642 [Full Text]  
• Lip, G. Y H (1996). Many patients are ineligible. BMJ 312: 51a-51 [Full Text]